Dr Brannan is chief medical officer at Karuna Therapeutics and a neuroscience drug development expert.

Stephen Brannan, MD

Stephen Brannan, MD, Chief Medical Officer of Karuna Therapeutics, talks more on their additional data presentation from the ACNP.

To get a closer look at the Phase 2 EMERGENT-1 poster that was presented at ACNP, see 

is chief medical officer at Karuna Therapeutics and a neuroscience drug development expert.

Videos

Hear details from the phase II trial of xanomeline-trospium and how it assists in the treatment of acute schizophrenia. 